Hoth continues to advance HT-001 in its Phase 2 CLEER-001 clinical trial targeting EGFR-inhibitor–associated rash, a significant unmet need in oncology supportive care. Recent progress includes: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results